MONOPOLY: predicting clinical benefit of dupilumab in adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP) - Dupilumab in patients with CRSwNP

Academisch Medisch Centrum0 个研究点目标入组 130 人开始时间: 待定最近更新: 2024年4月9日

适应症

试验速览

暂无简介。

•age < 18 years
•pregnancy
•patient is not able to complete SNOT-22 questionnaire in NL or EN
•strong indication for surgical treatment (e.g.: mucoceles)
•systemic diseases affecting the nose (e.g.: GPA, EGPA, sarcoid, primary
•ciliary dyskinesia, cystic fibrosis)
•antrochoanal polyps (isolated benign polyps originating from the mucosa of
•the maxillary sinus with a distinctive small stalk)
•inverted papilloma and malignant polyps
•acute upper or lower respiratory tract infections within 2 weeks before the
•inclusion visit
•use of systemic corticosteroids within 4 weeks before the inclusion visit
•need of continuous systemic corticosteroid treatment for other disease than
•systemic diseases preventing participation in the study (all comorbidities
•that have a higher impact on quality of life than CRSwNP and/or making the
•patient at risk during the study period)
•other systemical medical treatments influencing disease or primary and
•secondary study outcome measurements such as (non-)selective immunosuppressants
•(e.g.: azathioprine, methotrexate), excluding co-treatment with other type-2
•biologicals for indication of CRSwNP and/or Asthma.

发起方